Next Article in Journal
Biological Evaluation of Uridine Derivatives of 2-Deoxy Sugars as Potential Antiviral Compounds against Influenza A Virus
Next Article in Special Issue
Clinical and Neurobehavioral Features of Three Novel Kabuki Syndrome Patients with Mosaic KMT2D Mutations and a Review of Literature
Previous Article in Journal
Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome
Previous Article in Special Issue
Histone Lysine Methylation and Neurodevelopmental Disorders
Open AccessReview

Epigenomics of Major Depressive Disorders and Schizophrenia: Early Life Decides

Max Planck Institute of Psychiatry, Translational Psychiatry, 80804 Munich, Germany
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2017, 18(8), 1711; https://doi.org/10.3390/ijms18081711
Received: 30 June 2017 / Revised: 31 July 2017 / Accepted: 2 August 2017 / Published: 4 August 2017
(This article belongs to the Special Issue Epigenetics of Neurodevelopmental Disorders)
Brain development is guided by the interactions between the genetic blueprint and the environment. Epigenetic mechanisms, especially DNA methylation, can mediate these interactions and may also trigger long-lasting adaptations in developmental programs that increase the risk of major depressive disorders (MDD) and schizophrenia (SCZ). Early life adversity is a major risk factor for MDD/SCZ and can trigger persistent genome-wide changes in DNA methylation at genes important to early, but also to mature, brain function, including neural proliferation, differentiation, and synaptic plasticity, among others. Moreover, genetic variations controlling dynamic DNA methylation in early life are thought to influence later epigenomic changes in SCZ. This finding corroborates the high genetic load and a neurodevelopmental origin of SCZ and shows that epigenetic responses to the environment are, at least in part, genetically controlled. Interestingly, genetic variants influencing DNA methylation are also enriched in risk variants from genome-wide association studies (GWAS) on SCZ supporting a role in neurodevelopment. Overall, epigenomic responses to early life adversity appear to be controlled to different degrees by genetics in MDD/SCZ, even though the potential reversibility of epigenomic processes may offer new hope for timely therapeutic interventions in MDD/SCZ. View Full-Text
Keywords: epigenomics; early life adversity; major depression; schizophrenia; GWAS; EWAS; meQTL; eQTL epigenomics; early life adversity; major depression; schizophrenia; GWAS; EWAS; meQTL; eQTL
Show Figures

Graphical abstract

MDPI and ACS Style

Hoffmann, A.; Sportelli, V.; Ziller, M.; Spengler, D. Epigenomics of Major Depressive Disorders and Schizophrenia: Early Life Decides. Int. J. Mol. Sci. 2017, 18, 1711. https://doi.org/10.3390/ijms18081711

AMA Style

Hoffmann A, Sportelli V, Ziller M, Spengler D. Epigenomics of Major Depressive Disorders and Schizophrenia: Early Life Decides. International Journal of Molecular Sciences. 2017; 18(8):1711. https://doi.org/10.3390/ijms18081711

Chicago/Turabian Style

Hoffmann, Anke; Sportelli, Vincenza; Ziller, Michael; Spengler, Dietmar. 2017. "Epigenomics of Major Depressive Disorders and Schizophrenia: Early Life Decides" Int. J. Mol. Sci. 18, no. 8: 1711. https://doi.org/10.3390/ijms18081711

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop